Drug Discovery World

APRIL 3, 2024

A public-private consortium formed by the biotech Hemostatics, based at the Barcelona Science Park, the Clínica Universidad de Navarra (CUN) and the Institute of Chemical Research of Catalonia (ICIQ), has received €2.5 The post Validating a revolutionary therapy against lethal haemorrhage appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Laboratories Pharmacokinetics Treatment 130

Drug Discovery World

FEBRUARY 12, 2024

Leslie Orne, President and CEO, Trinity Life Sciences “AI and ML will play an increasingly important role in the clinical development and commercialisation of cell and gene therapies, which are typically targeted to small patient populations.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Drug Target Review

JANUARY 8, 2024

Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases.

Science 145

Science Disease FDA Approval Pharmaceutical Companies 145

LifeSciVC

APRIL 2, 2024

The quality of science – and the ability to distinguish it from other approaches – was the entry ticket to serious engagement. The science presents an opportunity and a challenge for us at Sionna. The science presents an opportunity and a challenge for us at Sionna. That science resonates with investors.

Science 68

Science Small Molecule International Clinical Development 68

Alta Sciences

OCTOBER 30, 2023

Top 10 Life Science Resources pmjackson Mon, 10/30/2023 - 16:16 There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for you. Catch up on what you may have missed below! The Altascientist : Issue No. Watch the video.

Science 52

Science Clinical Trials Pharmacokinetics Pharmacy 52

Drug Target Review

FEBRUARY 1, 2024

Historically, what has limited investor interest in funding neurological and psychiatric therapies in development? Investors have historically taken a ‘guilty until proven innocent’ approach to investing in neuroscience therapies. All stakeholders have benefited from these innovations.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Discovery World

JULY 2, 2024

DDW’s Diana Spencer takes a closer look into why Switzerland is such a life sciences powerhouse and how Swiss researchers are advancing new technology and tackling modern health challenges. Switzerland, however, boasts three (or arguably, four) separate yet complimentary centres of life science innovation.

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Discovery World

SEPTEMBER 12, 2022

If anything, this period has been a reminder that people are the primary reason we do what we do, and the Patient Access, Healthcare & People track at Advanced Therapies Europe 2022 allowed DDW’s Multimedia Editor Megan Thomas to share several reflections on the topic. .

Clinical Trials 130

Clinical Trials Trials Therapies Science 130

Drug Discovery World

MARCH 14, 2023

The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. This investor syndicate creates a very strong and committed shareholder base with a track record of supporting successful next generation companies.

Disease 130

Disease Treatment Science Clinical Development 130

The Pharma Data

OCTOBER 21, 2020

and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme. Of those participants who transitioned back to injectables, the median duration of oral therapy was 51 days.

Clinical Development 52

Clinical Development Therapies Clinical Trials FDA Approval 52

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

MAY 17, 2023

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with Dr Michael Pace, Global & Strategic Feasibility Expert at Rho.

Clinical Trials 130

Clinical Trials Trials Clinical Development Science 130

Drug Discovery World

MAY 17, 2023

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with Dr Michael Pace, Global & Strategic Feasibility Expert at Rho.

Clinical Trials 130

Clinical Trials Trials Clinical Development Science 130

The Pharma Data

FEBRUARY 24, 2022

Bayer announced today the initiation of the CONFIDENCE study, a Phase II, three-arm study that will investigate simultaneous initial combination therapy with finerenone and the SGLT2 inhibitor empagliflozin, compared with finerenone alone and empagliflozin alone respectively in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).

Clinical Development 52

Clinical Development Disease Therapies Treatment 52

The Pharma Data

JUNE 2, 2023

Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA FOSTER CITY, Calif. & –(BUSINESS WIRE)– Gilead Sciences, Inc. & SANTA MONICA, Calif.–(BUSINESS

Therapies 52

Therapies Clinical Development Treatment Trials 52

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

Therapies 52

Therapies FDA Clinical Trials Production 52

Drug Discovery World

MAY 6, 2024

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. This article takes a closer look at several key clusters in the region.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

Drug Discovery World

MAY 15, 2023

JD Mowery, Chief Executive Officer, Marykay Marchigiani, Chief Financial Officer and Sigma Mostafa, Chief Scientific Officer, KBI Biopharma With a 25-year track record of building organisations, Mowery will lead KBI and Selexis, both JSR Life Sciences companies.

Science 130

Science Laboratories Clinical Development Therapies 130

Drug Discovery World

JULY 15, 2024

Key takeaways The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research. This bodes well for potential future research and therapies,” she adds.

Research 130

Research Clinical Pharmacology Therapies RNA 130

Drug Discovery World

SEPTEMBER 14, 2023

Evaluating Immatics’ IMA203 TCR-T therapy, targeting PRAME, in combination with Moderna’s PRAME mRNA-based cancer vaccine. Moderna will lead the clinical development and commercialisation of cancer vaccines and TCER therapeutics resulting from the collaboration.

Vaccine 130

Vaccine Bioinformatics Clinical Trials Therapies 130

The Pharma Data

NOVEMBER 29, 2020

Prior to joining Gannex, Dr. Palmer was Head of Liver Disease Clinical Development at Takeda Pharmaceuticals. She has also held senior leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of NASH and other liver disease programs. ” About Ascletis.

Clinical Development 40

Clinical Development Disease Clinical Trials Pharmaceutical Companies 40

The Pharma Data

MARCH 27, 2021

Gilead Sciences, Inc. Gilead has outstanding research and clinical development programs across Virology, Immunology and Oncology, and I am tremendously excited to be joining an organization with such a deep and talented scientific core,” commented Dr. Martin.

Science 52

Science Research Pharmacy Clinical Development 52

The Pharma Data

MARCH 15, 2022

Global Head of Research and Development for Sanofi “ The collaboration with Blackstone will accelerate our ability to offer patients a subcutaneous anti-CD38 antibody therapy that we believe will be innovative and more convenient. 2 prior therapies, including lenalidomide and a proteasome inhibitor. Nicholas Galakatos, Ph.D.

Science 52

Science Treatment Clinical Trials Therapies 52

Precision for Medicine

JUNE 26, 2023

Baseline Control’s expertise will become part of Project Farma, Precision for Medicine’s existing biomanufacturing strategy and execution group, expanding the scope of its manufacturing solutions for life science companies and driving greater speed and efficiency in bringing new drugs to market.

Science 40

Science Small Molecule Clinical Research Engineering 40

Drug Discovery World

JUNE 15, 2023

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene (CGT) therapies for the benefit of patients worldwide. DDW’s Megan Thomas heard from attendees about key trends in the sector.

Regulations 130

Regulations Therapies Production Clinical Trials 130

The Pharma Data

SEPTEMBER 29, 2021

Patients are going to be randomized to receive either finerenone 10mg or 20mg or placebo on top of individually tolerated maximum labeled doses of a renin-angiotensin system (RAS)-blocking therapy like an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB).

Clinical Development 52

Clinical Development Disease Clinical Trials Trials 52

Conversations in Drug Development Trends

DECEMBER 7, 2023

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture. We are acutely aware that turnover in key project team personnel can lengthen project timelines and inflate clinical trial costs.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

Drug Discovery World

JUNE 27, 2023

It will be headquartered at the Monash Institute of Pharmaceutical Sciences (MIPS). The Drug Discovery Initiative at the University of Sydney is thrilled to collaborate with the Monash Institute of Pharmaceutical Sciences and WEHI to create this much needed national framework. MedChem Australia will fill this gap.

Drugs 130

Drugs Medical Chemistry Pharmacokinetics Science 130

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Licensing 52

Licensing Licensing Therapies Science 52

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Drug Target Review

FEBRUARY 29, 2024

From a very young age, I was drawn to science and medicine. This early exposure to bench science had a long-lasting impact. Through further research and work as a principal investigator on clinical studies for several central nervous system indications, I laid the groundwork for a career in gene therapy drug development.

Therapies 111

Therapies Disease Clinical Trials Science 111

Drug Discovery World

JANUARY 15, 2024

Jennifer Swantek, Director of the Foundation’s IBD Therapeutics Incubator programme, said: “We’re eager to deliver much needed, differentiated therapies to Crohn’s disease and ulcerative colitis patients as soon as possible.” of Perspective’s shares for up to $33 million.

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

Drug Discovery World

APRIL 26, 2023

Lucas Ferrari de Andrade, a co-author of the paper, is Assistant Professor of Oncological Sciences at Icahn Mount Sinai. The researchers caution that although TREM2-expressing bone marrow-derived macrophages have been implicated in other tumour types, recent studies suggest TREM2 inhibition is not universally therapeutic.

Clinical Development 130

Clinical Development Regulations Research Science 130

The Pharma Data

JANUARY 14, 2021

PRA Health Sciences selected for the study which will position Awakn at the Forefront of Psychedelic Research for Addiction Treatment. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Imperial College London and Chair of Awakn’s Scientific Advisory Board. About PRA Heath Sciences.

Science 52

Science Treatment Clinical Trials Clinical Development 52

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. Also in December, the company partnered with Atara Biotherapeutics to develop off-the-shelf T-cell immunotherapies for high mesothelin-expressing tumors. Photo courtesy of Bayer. We have set the bar high.

Therapies 52

Therapies Licensing Licensing Pharmaceuticals 52

Drug Discovery World

OCTOBER 4, 2022

Taking place at the ExCel in London from 4-5 October, ELRIG Drug Discovery 2022 is set to provide visitors with access to the latest trends, technologies and expertise driving the life sciences sector. . Cell and gene therapies. In the UK, effort has been made to scale-up the country’s cell and gene therapy manufacturing capabilities.

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

Drug Target Review

APRIL 3, 2024

Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences. Being an only child of non-academic parents, I learned to work and study independently early on.

Science 105

Science Clinical Development DNA Treatment 105